Op Sales +6.4% (Double-Digit ex-STELARA), FY26 Raised to $100.8B / $11.55 EPS, ICOTYDE and INLEXZO Off the Blocks — Maintaining Outperform, FV $190–220

Rating Action

Maintaining Outperform. Fair value range unchanged at $190–220. The Q3 2025 upgrade was underwritten by five propositions that have to keep clearing for the rating to hold; the Q4 2025 print validated the framework and the FY26 guide; the Q1 2026 print extends the validation. The two product launches that anchored the upgrade case — ICOTYDE in immunology and INLEXZO in bladder cancer — both have early commercial data that argues for the upper end of consensus, not the middle. The STELARA biosimilar drag is now bounded (we have lapped the cliff and are inside the post-cliff stable band). Daubert is bounded (the question is timing, not direction). Margin is the lone live debate; we treat the Q1 step-down as front-loaded launch spend, not structural, because management held the FY26 +50bps op-margin guide.

Rating Arc

• Q2 2025 (Initiating at Hold). Five reservations: STELARA biosimilar curve still descending (-42% expected to widen), talc Daubert binary by 2026, MedTech IM-margin compression of ~350bps, post-print breakout removed valuation cushion, 2H 2025 pipeline catalysts (INLEXZO/icotrokinra/CAPLYTA-MDD/subcu RYBREVANT) unvalidated.
• Q3 2025 (Upgrading to Outperform). All five reservations cleared in a single print: STELARA cliff plateauing on the HUMIRA-Y2 analog (-42% in line), DePuy Synthes orthopaedics spin announced (+75–100bps to remaining MedTech growth and margin), Daubert bounded "by 2026," pipeline catalysts validated (INLEXZO approved, CAPLYTA-MDD/subcu RYBREVANT/icotrokinra advancing), management pre-flagged 2026 above Street consensus.
• Q4 2025 (Maintaining Outperform). The FY26 framework validated the upgrade: Q4 op +7.1% / FY25 op +5.3% / FY26 guide $100.5B reported / $11.53 reported EPS / TREMFYA +65% / Daubert special master report excluded plaintiff junk-science expert opinions. The clean print, credible FY26 framework and Daubert visibility we needed all printed in one release.
• Q1 2026 (Today — Maintaining Outperform). What the Q3 upgrade was underwriting against, the Q1 print directly delivers. ICOTYDE 1,500 prescriptions and >1,000 prescribers in the first weeks; INLEXZO new-patient insertions +90% wk-over-wk post-J-code; STELARA at the modelled trough but IM still +7.4%; FY26 guide nudged up not down ($100.8B / $11.55). Daubert is silent on the call — the legal tail is no longer asked. The framework holds.

Results vs. Consensus

*PY GAAP EPS reflected the ~$7B talc reserve reversal in Q1 2025 (a one-time benefit). The YoY comparison is mechanically distorted; adj EPS is the cleaner read.

Headline: a clean revenue and EPS beat, with the "ex-STELARA" lens (which is the one that matters for the run-rate exit) showing the company growing at double-digit rates on the underlying portfolio. The margin print is the soft spot — 410bps of adj pretax compression is real — but management's accounting is plausible: heavier first-half launch investment (front-loaded against ICOTYDE/INLEXZO/CAPLYTA), MedTech tariff headwind in COGS, and tough one-time-item comps in 2025. The FY26 +50bps op-margin guide was reaffirmed, which is the right operative test.

Segment Performance — Innovative Medicine ($15.4B, +7.4% op)

The segment grew $15.4B at +7.4% operational despite a 920bps drag from STELARA — ex-STELARA, IM grew +16.6%, with 11 brands posting double-digit growth. Acquisitions (Intra-Cellular ⇒ CAPLYTA) added 180bps. The setup we underwrote a quarter ago — STELARA at the trough, the new-launch portfolio absorbing the slack — is the print we got.

Oncology

• DARZALEX $4.0B, +17.8% op. Now the #1 product in the company. Driven by share gains of 5.9 points across all lines of therapy and ~12 points in frontline. The franchise drives the multiple-myeloma flywheel for CARVYKTI/TECVAYLI/TALVEY.
• CARVYKTI $600M, +57.4%. Still ramping with site expansion and share gain.
• TECVAYLI +30.1% with sequential growth +14.2%. The April FDA approval of TECVAYLI + DARZALEX FASPRO for relapsed/refractory MM positions the regimen as potential second-line standard of care — a meaningful expansion from a third-line label.
• TALVEY +72.8%. Community-setting expansion driving share gain.
• RYBREVANT + LAZCLUZE $257M, +80.5%; sequential +18.8%. Both 1L and 2L share. RYBREVANT FASPRO (subcu monthly) approved this quarter; FDA breakthrough therapy designation in advanced head-and-neck cancer with new combination data.
• ERLEADA +16.2%. Continued share gain in prostate cancer.
• INLEXZO >$30M in Q1 — first disclosure. Outperforming all recent NMIBC launches on unique-patient metric. 1-in-5 eligible patients started on INLEXZO in Q1 in the BCG-unresponsive population. Permanent J-code received April 1; new-patient insertions +50%+ wk-1, ~+90% wk-2 post-J-code. The reimbursement-gated launch dynamic we flagged at upgrade is now resolving.

Immunology

• TREMFYA +63.8%. Fastest-growing IL-23 in the U.S. and now share leader in new-patient starts in IBD. On track to exceed $10B peak.
• STELARA -61.7%. The modelled trough quarter. -540bps drag on the enterprise. The next four quarters lap the steepest part of the curve and the YoY drag thins meaningfully.
• ICOTYDE (icotrokinra), launched March 2026. First and only oral peptide IL-23 receptor blocker. Patient one received drug within 24 hours of approval. ~1,500 patient prescriptions written in the first weeks; >1,000 unique prescribers. KOL feedback emphasizes a differentiated label (no lab monitoring, no black box, no drug interactions). ICONIC-ASCEND (head-to-head vs. TYK2) imminent. Psoriatic-arthritis Phase III readout later this year. The launch curve so far is consistent with the "potential to be one of our largest products ever" framing.

Neuroscience

• SPRAVATO +44.5%. Demand from physicians and patients still strong.
• CAPLYTA $270M. aMDD (adjunctive major depressive disorder) launch is delivering CAPLYTA's highest-ever new-patient starts across all indications. Bipolar-mania data later this year. Management reiterated $5B+ peak sales potential.

Segment Performance — MedTech ($8.6B, +4.6% op)

MedTech printed +4.6% operational, modestly below the Q4 2025 trajectory and below where the bull case wanted it. The shape, however, is what matters: cardiovascular — the segment that the Abiomed and Shockwave acquisitions exist to bend the growth curve of — is doing the work, while surgery and ortho carry the seasonal/transition drag. Q1 is structurally MedTech's softest quarter.

• Cardiovascular. Electrophysiology +9.5% (VARIPULSE adoption, U.S. submission of dual-energy THERMOCOOL SMARTTOUCH SF). Abiomed +14.4% (Impella 5.5 / CP, supported by the DanGer Shock 10-year survival data published last August). Shockwave +18.1% (coronary + peripheral, with the C2 Aero coronary catheter launching this year). The Q3 upgrade case for cardiovascular is intact — if anything, accelerating.
• Surgery +1.2%. ~30bps divestiture drag plus China VBP and competitive pressure in energy/endocutters; OTTAVA (robotic surgery) IDE-2 trial in inguinal hernia underway. Surgery is the segment that requires patience — OTTAVA + MONARCH commercialization in 2H is the catalyst.
• Vision. Contact lenses +2.7% (ACUVUE OASYS 1-Day MAX line); Surgical Vision +6%. The U.S. -3% in surgical reflects new competitive entrants on TECNIS — the FDA approval of TECNIS PureSee this quarter (the first U.S. EDOF IOL with no contrast-sensitivity warning) is the launch that should reverse U.S. surgical 2H.
• Orthopaedics +3.2%. Under new leadership (Namal Nawana). Mid-2027 separation timeline reaffirmed; management explicitly "evaluating all separation vehicles that create shareholder value." The strategic separation thesis (a transaction structure, not just a spin) remains live.

Key Topics & Management Quotes

1. ICOTYDE: launch curve looks like the upper end

"The product was approved in March. And we're really, really happy with what we believe is a very differentiated label for the product… In terms of early uptake, we're seeing so far about 1,500 patients already that prescriptions have been written for that are going into access and patient support service center, so already 1,500 and already over 1,000 unique customers that are writing." — Jennifer Taubert, EVP & Worldwide Chairman, Innovative Medicine

The single data point that will define this quarter's narrative. 1,500 prescriptions in <30 days from approval, with >1,000 distinct prescribers, suggests broad — not narrow — adoption. The label differentiation (no lab monitoring, no black box, no drug interactions, a once-daily oral instead of a biologic injection) is the qualitative case for ICOTYDE displacing both topicals (market expansion) and biologic-naive patients (share). John Reed's framing — that 70–80% of biologic-eligible autoimmune patients are not currently on a biologic — is the addressable-market argument.

2. INLEXZO: J-code goes live, demand inflects

"What we saw in the first week was actually a over 50% increase in new patient insertions and the second week we that we have under our belt, we actually saw that jump up to almost 90% increase in new patient insertion. So consistent with what we've articulated on our expectations for this product once there's certainty reimbursement following the J-code, we're seeing play out in practice so far in the first couple of weeks." — Jennifer Taubert

This is the data the bear case asked for. INLEXZO is a delivery-system-plus-drug combination launched into a market where reimbursement uncertainty is the single biggest near-term obstacle. The April 1 J-code is the unlock; the +50%/+90% wk-over-wk insertion growth across the first two weeks is the unlock playing out in real time. Q1 sales just above $30M is a small base, but the second-derivative argument (post-J-code growth) is the right read for a product that just got the procedure-code anchor. Right behind it: erdafitinib in IRDA (the next-generation device) for intermediate-risk NMIBC, with biomarker-defined CR rates >90% per management. The intravesical drug-releasing-system platform is broader than a single asset.

3. STELARA: at the modelled trough

"Worldwide sales of $15.4 billion increased 7.4% despite an approximate 920 basis point headwind from STELARA which underscores the continued strength of our key brands and new launches." — Darren Snellgrove, VP IR

STELARA -61.7% is the steepest YoY drag we will see for the franchise in this cycle. Two consecutive quarters of -50%+ have effectively reset the base; the YoY comp progressively eases through the rest of FY26 and FY27. The structural read is unchanged: STELARA is shrinking on schedule, IM is growing through it, and the new launches (TREMFYA, ICOTYDE, CAPLYTA, the multiple-myeloma stack) are absorbing the absolute-dollar gap.

4. Double-digit growth by end of decade: management reasserts the case

"If you look at the first quarter of 2026, we are already delivering double-digit growth as total Johnson & Johnson when you exclude the STELARA. So it's already happening today." — Joaquin Duato, Chairman & CEO

The CEO is explicit that the "line of sight to double-digit growth by end of decade" thesis does not depend on M&A — it is built off the existing portfolio plus already-launched assets. Specific underestimation calls: ICOTYDE in PsA + IBD; RYBREVANT in NSCLC + head-and-neck + colorectal; INLEXZO in NMIBC; cardiovascular launches (Impella ECP, next-gen PFA); OTTAVA + DePuy spin-induced mix lift. Plus DARZALEX U.S. royalty roll-off in 2029 as an operating-leverage tailwind. That last item is the under-discussed point; we will return to it in a forthcoming model update.

5. MedTech: Q1 4.6% is seasonal, not structural

"Q1 unfolded as we expected the year to start seasonally quieter but operationally solid… nothing in the quarter changes our confidence in further acceleration as we look towards Q2 and the remainder of 2026." — Tim Schmid, EVP & Worldwide Chairman, MedTech

The +4.6% MedTech print is the line we will get the most pushback on. The framing we accept: Q1 is structurally the lightest quarter, the cardiovascular subsegments are growing 9–18%, surgery's 1.2% absorbs a transformation drag and a measurable China-VBP step-down, vision's surgical line in the U.S. is working through new entrants until PureSee launches. We are watchful but not alarmed. The MedTech compression bear case becomes load-bearing if Q2 does not accelerate.

Guidance & FY26 Update

Modest beat-and-raise — the kind that says, "the FY26 framework we set in January was right, with one quarter of upside." The 53rd-week benefit (~100bps) referenced in January is unchanged; FX is roughly neutral vs. the prior euro reference. The op-margin guide of at least +50bps for the full year is the variable we monitor closest, given Q1's 410bps adj pretax compression; management's framing is that launch spend is front-loaded and the back-half delivers the leverage. We accept the framing for Q1, but it is the live test.

Pipeline & Catalysts

• ICOTYDE. ICONIC-ASCEND head-to-head vs. TYK2 inhibitor — readout imminent. Psoriatic-arthritis Phase III readout later 2026. IBD (UC + Crohn's) Phase III enrollment ongoing; data later in the program.
• INLEXZO. Q1 sales just above $30M (first disclosure); J-code April 1; expansion into broader NMIBC populations beyond BCG-unresponsive over coming years. Japan PMDA accepted submission on single-arm data — a regulatory first, per management.
• IRDA (intravesical drug-releasing system w/ erdafitinib). Three-month dosing vs. INLEXZO's three-week; biomarker-defined CR >90%. Behind INLEXZO in the platform.
• JNJ-4804 (TREMFYA + golimumab co-antibody). Phase II IBD readouts at upcoming medical meeting; Phase III underway. Potential first-in-class co-antibody for IBD non-responders.
• RYBREVANT. Breakthrough designation in head-and-neck; OrigAMI-5 ongoing. Subcu (FASPRO) approved Q1.
• TREMFYA. Psoriatic-arthritis structural-damage approval pending in 2026.
• CAPLYTA. Bipolar-mania data later this year.
• MedTech. OTTAVA + MONARCH approvals/launches expected by year-end (both potential 2H catalysts). VARIPULSE Pro U.S. submission. ETHIZIA biosurgery. Dual-energy THERMOCOOL SMARTTOUCH SF U.S. submission.
• Capital allocation. December 8, 2026 Enterprise Business Review (long-term strategy, double-digit growth bridge). Halda Therapeutics oncology platform deal closed earlier in 2026 — a small early-stage tuck-in consistent with management's stated "sweet spot."

Analyst Q&A — What Was Asked, What It Tells Us

Eight questions, six analysts, ICOTYDE and the new-launch portfolio dominating the discussion. The most informative read of an earnings call is the distribution of analyst questions, and this distribution tells you the buy-side is now under-modelling the launch curve, not the legacy drag.

Terence Flynn (Morgan Stanley) — ICOTYDE positioning, ramp, sampling.

Two-part on ICOTYDE positioning & reimbursement. Taubert took the question and emphasized the differentiated label, day-one launch readiness (1st patient on drug within 24 hours), 1,500 prescriptions / 1,000+ unique prescribers in the first weeks, and "positive" payer conversations. John Reed flagged the psoriatic-arthritis study readout later this year. Management is leaning into the launch as the story.

Larry Biegelsen (Wells Fargo) — MedTech end-market and Q1 vs. Q4 deceleration.

The pre-emptive question: MedTech grew slightly slower in Q1 than Q4, against an "easy comp." Schmid's response was that 210bps of one-time benefit in 1Q25 was a 2024-event lap (so Q1 2026 comp was actually meaningfully tougher than headline), Q1 is seasonally light, end-markets are solid, weather impact in Jan/Feb was non-material. Management is asking the buy-side to look at the 2H acceleration, not Q1 vs. Q4 sequencing.

Asad Haider (Goldman Sachs) — Bridge to double-digit growth by end of decade; role of BD.

Duato gave the cleanest articulation we have heard: the bridge is the existing portfolio plus the four under-modelled launches (ICOTYDE, RYBREVANT, INLEXZO, cardiovascular launches), the DePuy Synthes separation lifting growth and margin mix, and DARZALEX U.S. royalty roll-off in 2029 as op-leverage. Critically: BD is not in the model. The double-digit-by-decade-end target is built off currently-owned assets. M&A is upside, not pre-condition.

Christopher Schott (JPMorgan) — ICOTYDE prescriber mix; psoriasis vs. IBD long-term split.

Taubert: too early to give breakdown by switch source, but ICOTYDE positions as first-line systemic in psoriasis (with patients cycling on topicals being the main expansion lever) and as a balanced opportunity across psoriasis + IBD long-term — a different shape from TREMFYA (where IBD is dominant). Reed reinforced the autoimmune-undertreatment statistic (70–80% of biologic-eligible patients not on a biologic). The implication: ICOTYDE's TAM is meaningfully larger than current psoriasis biologic market.

Shagun Singh (RBC) — Abiomed post-ACC; IVL competition; MedTech in the double-digit bridge.

Schmid framed Abiomed as evidence-anchored (10-year DanGer Shock data showing 16.3% absolute mortality reduction) with no near-term competitive substitute; Shockwave defended on portfolio (5th-gen launching vs. competitors' 1st-gen 2017-equivalent), evidence (~25,000 published patient outcomes), and presence (2+ generators in 1,700+ U.S. hospitals). MedTech as "mid-single-digit player into a higher single-digit player" over the back half of the decade — supported by OTTAVA + MONARCH commercialization. The Schmid characterization is the right one to underwrite.

Alexandria Hammond (Wolfe) — ICOTYDE prescriber education; ICONIC-ASCEND impact.

Reed reiterated the "best-in-disease" ICOTYDE profile against TYK2; Taubert flagged "investing big" in launch (field, patient access, education, DTC under evaluation). The investment intensity is part of the margin compression we see in Q1 — and it is well-spent if the early uptake metrics scale.

Joanne Wuensch (Citi) — Vision/U.S. surgical -3% recovery.

Schmid: U.S. surgical decline is competitive pressure on TECNIS Odyssey from new entrants; TECNIS PureSee U.S. launch later this year is the reversal catalyst. Already 500K eyes globally on PureSee with very strong patient feedback. We treat this as a 2H catalyst.

David Risinger (Leerink) & Matt Miksic (Barclays) — JNJ-4804 IBD; INLEXZO commercial rollout.

Reed framed JNJ-4804 as potentially first-in-class co-antibody (TREMFYA + golimumab) for IBD non-responders, Phase II readout at upcoming medical meeting. Taubert on INLEXZO went deepest on the J-code unlock data (the +90% wk-over-wk metric is the data point of the call) and the dual-engine go-to-market — J&J is uniquely able to bring both an IM franchise and a MedTech training/site-of-care infrastructure to a delivery-system-plus-drug product.

What is conspicuously absent. Eight Q&A slots; not one talc/Daubert question. Three quarters ago, this would have been the lead question. The legal-tail question is no longer a thing analysts ask — either because the special-master report and the bounded ruling have de-risked it sufficiently, or because the oncology/immunology launch story has crowded it out of the room. Either way, the silence is constructive.

What They Are Not Saying

• No talc/Daubert update on the call. Not even a question. The Q4 special-master report excluded the most damaging plaintiff expert opinions; the substantive ruling remains expected by 2026. That the topic has now exited the analyst agenda is itself a tell.
• No new BD update beyond Halda. Halda Therapeutics (oncology platform) was a small early-stage tuck-in; nothing larger is teed up. Duato's framing — capital priority is internal launch investment over M&A — is consistent with a CEO who does not need to do a deal to hit guidance.
• INLEXZO Q1 sales just above $30M but no full quarterly disclosure cadence yet. When asked, Snellgrove deferred ("we actually don't disclose the [INLEXZO] sales at this point in time"). Implies the disclosure cadence catches up as the product moves out of launch quarter and into more material contribution — a good problem.
• Margin compression characterization is launch-spend-driven, not structural. Management held the +50bps FY26 op-margin guide despite 410bps Q1 adj pretax compression. The unsaid: H1/H2 op-margin shape is materially weighted to H2. Watch the Q2 print.
• DePuy Synthes separation: "evaluating all separation vehicles." First mentioned in October as a spin; the language now explicitly includes alternative structures (e.g., merger/swap). Mid-2027 timing. The ortho-spin-as-mix-lift case remains in the model; the structure is the variable.

Market Reaction

The print landed early Tuesday April 14, 2026. Shares were up roughly 0.5% at ~$239 in the early session — a measured move, against an already strong YTD (~+15% into the print). The muted reaction is consistent with the framework: the print does not change the FY26 framework; the FY26 framework is what re-rated the stock between Q3 2025 and Q1 2026; and the launch metrics — while objectively strong — are early enough to be characterised as "needs another quarter." The asymmetry inside the print (ICOTYDE Rx + INLEXZO J-code data + a $0.3B/$0.02 raise) is more constructive than the tape suggests; we read the tepid reaction as opportunity rather than thesis-undermining.

Street Perspective

The constructive view on the Street post-print emphasizes the launch-portfolio data as confirming the "cleanest growth story in healthcare" framing — double-digit ex-STELARA today, ICOTYDE launch curve consistent with a multi-billion-dollar peak-sales potential, INLEXZO J-code unlock plus broader-population expansion ahead, and an FY26 guide raise (however modest) reinforcing that the 2026 acceleration is intact. The bridge to double-digit growth by end of decade is supported by an internal portfolio plus DARZALEX royalty roll-off as op-leverage in 2029.

The cautious view focuses on the MedTech +4.6% print being below where Q4's run-rate had it pointing, the 410bps Q1 adj pretax margin compression as a sign that launch-spend escalation is more than offsetting the operating leverage that the FY26 +50bps guide assumes, and the talc/Daubert tail being merely deferred (not definitively resolved). On the cautious view, the FY26 guide-raise is small enough ($0.3B / $0.02 EPS) to be interpreted as in-line ex-FX, with the heavy lifting still ahead.

Our read sits closer to the constructive view. The launch-portfolio data is the most informative quarter for ICOTYDE and INLEXZO that we will see in the rest of 2026; the J-code +90% inflection is a near-textbook unlock for a delivery-system-plus-drug product; the MedTech print is seasonally explainable and the 2H catalysts (OTTAVA, MONARCH, PureSee, ETHICON 4000 Europe) are concrete; and the talc-tail's exit from the analyst agenda is itself information.

Model Implications

• FY26 sales. Move to mid-to-upper end of $100.3–101.3B reported range; midpoint $100.8B is the right anchor. Operationally, $100.0–$100.5B at midpoint is consistent with the +5.9–6.9% guide.
• FY26 adj reported EPS. Anchor at $11.55 midpoint; tilt toward upper half of $11.45–$11.65 if H2 op-margin expansion materializes per guide.
• STELARA modelling. Anchor STELARA Q1 -61.7% as the trough; model gradual easing through 2026 as YoY comp normalizes off the cliff. Steady-state run-rate (~2027) at substantially below 2024 base.
• ICOTYDE. Lift early-launch trajectory; first-year sales conservatively in the low hundreds of millions on full-year contribution; longer-term peak modelled at $5–10B+ contingent on ICONIC-ASCEND data + IBD readouts. Management's "potential to be one of our largest products ever" supports upside on ICOTYDE assumptions in the long-range model.
• INLEXZO. Q1 base of $30M+ plus +90% wk-over-wk insertion growth post-J-code argues for a steeper FY26 ramp; size at multi-hundred-million for FY26 contingent on payer breadth.
• TREMFYA. Maintain $10B+ peak; PsA structural-damage approval is a 2026 acceleration trigger.
• CAPLYTA. $270M Q1 + aMDD launch supports model glide-path to $5B+ peak.
• MedTech. Reaffirm mid-single-digit FY26 (with the year-end-of-decade transition to higher-single-digit). DePuy Synthes separation impact on remaining MedTech to be sized post-transaction-structure announcement.
• Margin. Hold FY26 +50bps op-margin guide as the working assumption; downgrade scenario triggers if Q2 does not show meaningful margin recovery.
• Capital allocation. Dividend +3.1% (64th consecutive raise); FCF $21B; $55B U.S. manufacturing/R&D commitment 22% deployed; M&A capacity ample but not the priority near-term.

Thesis Scorecard

Valuation

We hold the fair-value range at $190–220 per share, set at the Q3 2025 upgrade. The case has not weakened in two quarters — if anything, the launch-curve evidence on ICOTYDE and INLEXZO is more concrete than we underwrote. We are watchful on margin and MedTech sequencing, but the core thesis — that the post-STELARA, pre-DARZALEX-royalty-roll-off period (2026–2028) sets up an op-leverage step-up that the Street is not yet fully crediting — is intact. The valuation multiple should re-rate as the $100B / $11.55 base is delivered in real-time and the 2027 step-function (ICOTYDE scale, JNJ-4804, OTTAVA, INLEXZO broader-population expansion, DePuy separation completion) becomes visible.

What We Are Watching

• Q2 2026 margin recovery. Op-pretax margin must show H2-weighting evidence. Q1 -410bps comp is digestible only if it is genuinely launch-spend phasing, not the start of structural compression.
• ICOTYDE NRx mix and payer breadth. By Q2, the "new vs. switch" breakdown should be available. Ideal: high "new-to-systemic" share (market-expansion) plus broad payer access (no narrow specialty PA).
• ICONIC-ASCEND head-to-head readout. Imminent. Strong differentiation vs. TYK2 anchors the "best-in-disease" case.
• INLEXZO disclosure cadence. When does management start reporting INLEXZO quarterly explicitly? The "not at this point in time" deferral suggests next disclosure when the base is more material.
• JNJ-4804 IBD Phase II readouts. Upcoming medical meeting. First-in-class co-antibody is a category-creating asset if it works.
• OTTAVA + MONARCH. 2H launches both possible. Robotic-surgery commercialization is a multi-year build, but visible progress in 2H is needed for the MedTech-acceleration narrative.
• DePuy Synthes separation structure. "All vehicles" framing leaves the door open to a transaction (e.g., RMT/Reverse Morris Trust) rather than a clean spin. Structure decision matters for shareholder math.
• Daubert ruling. Substantive ruling expected by 2026. The market is no longer pricing the tail; an adverse ruling would re-introduce risk premia.
• December 8 Enterprise Business Review. Long-range strategy + double-digit-growth bridge. Is the stage where management quantifies what is currently a qualitative end-of-decade target.